Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Zynerba Pharma CS (NQ: ZYNE ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Oct 10, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Zynerba Pharma CS < Previous 1 2 Next > Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions October 04, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 September 29, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium September 14, 2023 Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment... From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE September 05, 2023 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sovos Brands, Inc. (Nasdaq - SOVO), Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. August 24, 2023 From Brodsky & Smith LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Chindata Group Holdings Limited (Nasdaq - CD), Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID) August 14, 2023 From Brodsky & Smith LLC Via GlobeNewswire ZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to Shareholders August 14, 2023 From Halper Sadeh LLC Via Business Wire Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting August 08, 2023 Annual Meeting to Reconvene on August 25, 2023 at 9:00 a.m. EDT From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting July 25, 2023 Annual Meeting to Reconvene on August 11, 2023 at 9:00 a.m. EDT From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting June 28, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 20, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting June 13, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting May 23, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights May 15, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference April 12, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference April 05, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights March 28, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank March 13, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference March 07, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference March 01, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome January 11, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome December 21, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology December 05, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology November 29, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders November 28, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome November 15, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights November 14, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome November 02, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit October 17, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit October 10, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.